At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32,450 enrolled
Drug / intervention
AZD1222 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
In Brief
A Phase 3 clinical trial evaluating AZD1222 and Placebo for COVID-19 and SARS-CoV-2. Completed, enrolled 32,450 participants across 84 sites in 3 countries.
Detailed Summary
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2
CountriesChile, Peru, United States
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionMar 2021
Study CompletionFeb 2023
TodayJul 2026
First PostedAug 18, 2020
Enrollment StartAug 28, 2020
Primary CompletionMar 5, 2021
Study CompletionFeb 10, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.9 years ago
Interventions
AZD1222biological
AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
Placebobiological
Commercially available 0.9% (n/V) saline for injection.